Scitke

Tag: Viagra

  • Viagra Cuts Alzheimer’s Risk by Over 50%

    Viagra Cuts Alzheimer’s Risk by Over 50%

    Researchers in the US, through an analysis of medical insurance data combined with laboratory research on the genetic and neurological impacts of sildenafil, an FDA-approved drug for erectile dysfunction often marketed as Viagra, have affirmed the medication's potential in preventing critical proteins in nerve cells from forming harmful tangles, suggesting its potential as a therapy for reducing the risk of Alzheimer's disease.
    Credit: Deposithphotos

    Researchers in the US, through an analysis of medical insurance data combined with laboratory research on the genetic and neurological impacts of sildenafil, an FDA-approved drug for erectile dysfunction often marketed as Viagra, have affirmed the medication’s potential in preventing critical proteins in nerve cells from forming harmful tangles, suggesting its potential as a therapy for reducing the risk of Alzheimer’s disease.

    Multiple studies have consistently shown that phosphodiesterase (PDE) inhibitors, which block enzymes, not only enhance blood flow in the penis but also have the potential to prevent the neurodegeneration associated with dementia.

    Sildenafil’s Potential in Improving Cognitive Function and Memory Through Tau Protein Regulation

    This potential isn’t surprising, given that PDEs play a role in nerve signaling pathways that affect neuroplasticity. Previous animal studies have indicated that the PDE inhibitor sildenafil can decrease the excessive phosphorylation of ‘tau’ proteins in nerve cells, which prevents them from forming toxic tangles, thereby improving cognitive function and memory.

    However, not all research has yielded positive results, with some studies failing to observe any effects at the population level. Additionally, while these drugs may have neurological effects, the exact mechanisms behind them are not fully understood.

    In the US, researchers utilized neuron cell cultures derived from stem cells donated by Alzheimer’s patients to investigate the metabolic and genetic activity underlying the therapeutic effects of sildenafil. After five days of treatment, these cultured neurons exhibited significantly reduced levels of tau proteins with excess phosphorus, indicating sildenafil’s ability to protect brain cells.

    Impact of Sildenafil on Gene Expression Patterns and Alzheimer’s Pathology

    Analysis of the cell DNA’s messages revealed numerous gene expression changes, many of which were related to inflammation, impaired nerve communication, and regulation of nerve cell structures. While further research is necessary to elucidate how these subtle influences contribute to Alzheimer’s pathology, understanding the key gene families affected by sildenafil lays a foundation for comprehending its mechanisms of action and potentially the origins of Alzheimer’s.

    Another aspect of the study involved employing artificial intelligence to identify indications of sildenafil’s effectiveness at a population level. Previous research utilizing medical insurance data has suggested that sildenafil could lower the risk of Alzheimer’s disease by approximately 60 percent.

    However, these studies relied solely on a single insurance database, potentially overlooking variables that could lead to different conclusions. Additionally, previous research suggested that patients undergoing treatment for pulmonary hypertension (PH), a condition involving high blood pressure in the lungs, did not experience the same reduction in dementia risk.

    Investigation of Sildenafil’s Effectiveness Across Pulmonary Hypertension Treatments

    In their analysis, the researchers considered four treatments commonly prescribed for PH. They not only confirmed that sildenafil reduced the risk of Alzheimer’s by approximately 60 percent but also discovered that it lowered the risk in individuals with pulmonary hypertension.

    Cleveland Clinic biomedical informatician and co-first author Feixiong Cheng expressed satisfaction with the computational integration of a large amount of data, highlighting the observation of sildenafil’s effects on human neurons and real-world patient outcomes.

    “We believe our findings provide the evidence needed for clinical trials to further explore the potential effectiveness of sildenafil in Alzheimer’s disease patients,” Cheng stated.

    Given that sildenafil already has FDA approval for erectile dysfunction, demonstrating its safety and efficacy in reducing Alzheimer’s risk could offer health authorities a swift solution to address the escalating dementia rates.

    With aging populations worldwide, the number of individuals living with dementia is expected to nearly double every 20 years, increasing from approximately 80 million by the end of this decade to nearly 140 million by the middle of the century.

    Read the original article on: Science Alert

    Read more: Viagra use Tied to 18% Lower Alzheimer’s Risk in Men

  • Viagra use Tied to 18% Lower Alzheimer’s Risk in Men

    Viagra use Tied to 18% Lower Alzheimer’s Risk in Men

    Phosphodiesterase type 5 inhibitors like Viagra are primarily recognized for their efficacy in treating erectile dysfunction. However, a study involving close to 270,000 men has contributed to the increasing evidence suggesting that these medications could also reduce the likelihood of developing Alzheimer's disease.
    Scientists found a surprising link between erectile dysfunction medication use and Alzheimer’s risk 
    Depositphotos

    Phosphodiesterase type 5 inhibitors like Viagra are primarily recognized for their efficacy in treating erectile dysfunction. However, a study involving close to 270,000 men has contributed to the increasing evidence suggesting that these medications could also reduce the likelihood of developing Alzheimer’s disease.

    Researchers from University College London (UCL) examined 269,725 male individuals in the UK, averaging 59 years old, without cognitive impairment, but diagnosed with erectile dysfunction. Over a five-year period, the participants were divided into two groups: those prescribed erectile dysfunction medications like sildenafil (Viagra) (accounting for 55% of the cohort) and those who did not undergo such treatment for their condition (comprising 45% of participants).

    Examining Alzheimer’s Risk in Relation to Erectile Dysfunction Medication Usage

    The study found that out of 1,119 participants diagnosed with Alzheimer’s disease, 749 were using erectile dysfunction medications, while 370 were not. However, when adjusted for person-years (reflecting both the number of individuals in the study and their duration of participation), the prevalence of Alzheimer’s was 8.1 cases per 10,000 person-years among those taking medication, compared to 9.7 cases per 10,000 person-years in those not using erectile dysfunction drugs.

    After adjusting for factors like age, smoking, and alcohol consumption, the researchers observed an 18% lower risk of Alzheimer’s disease among individuals taking medication.

    Ruth Brauer, a study author from University College London, emphasized the need for treatments to prevent or delay Alzheimer’s disease progression, alongside the advancements in treatments targeting amyloid plaques. Brauer described the results as encouraging and deserving of further investigation.

    Impact of Frequency of Medication Use and Age on Alzheimer’s Risk Reduction

    Furthermore, the study indicated that the risk reduction was most significant among men who used the medication frequently, with 20 or more prescriptions during the study period. Additionally, the protective effect of the drugs appeared more pronounced in men aged 70 and older compared to those under 70.

    While phosphodiesterase type 5 inhibitors (PDE5Is) had shown promise in animal studies, their effects in human populations have been inconclusive. Sildenafil, the first PDE5I, initially developed for hypertension and angina treatment, revolutionized erectile dysfunction therapy. Repurposed in 2005 for pulmonary arterial hypertension, sildenafil dilates blood vessels to enhance blood flow.

    Research has also explored the potential of using sildenafil as a treatment for obesity and to reduce the risk of colorectal cancer.

    Impact of Phosphodiesterase Type 5 Inhibitors (PDE5Is) on Brain Function and Alzheimer’s Disease

    The drug’s mechanism of increasing blood flow may have implications for brain function by enhancing circulation, potentially preventing the accumulation of toxic proteins associated with Alzheimer’s disease. Previous animal studies have shown that phosphodiesterase type 5 inhibitors (PDE5Is) also elevate levels of the neurotransmitter acetylcholine, which is involved in memory, learning, and involuntary muscle movement, with low levels linked to Alzheimer’s.

    Despite these promising findings, the researchers urge caution, considering this study as an initial step requiring further clinical investigation to fully comprehend how PDE5Is impact the brain. Previous research has faced skepticism, with experts highlighting lifestyle factors and other variables that can complicate interpretation in such studies.

    Ruth Brauer stated, “More research is needed to validate these findings, understand the potential benefits and mechanisms of these drugs, and determine the optimal dosage. A randomized, controlled trial involving both male and female participants is necessary to assess whether these results apply to women as well.”

    Read the original article on: New atlas

    Read more: By 75, About 50% of the Population May Experience a Mental Health Condition